- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00340119
Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis
Prospective Study of Inflammatory Markers and Genes as Predictors of Atherosclerotic Cardiovascular Disease in Dialysis Patients
This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patients on dialysis is extraordinarily high, accounting for about 50 percent of deaths. Blood levels of inflammatory markers are elevated in these patients, strongly predicting illness and death from CVD. The discovery of gene variants related to the inflammatory process in atherosclerotic CVD may lead to better medical treatments and improved survival in patients with end-stage kidney disease.
Participants of John's Hopkins University's CHOICE (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease) program are included in this study. Blood samples previously collected from these patients will be analyzed in the laboratory for genes that might be associated with the inflammatory process and atherogenesis.
Přehled studie
Postavení
Podmínky
Detailní popis
Background:
The CHOICE (Choices for Healthy Outcomes in Caring for End stage renal disease) study is a national prospective cohort study of 1,041 incident dialysis patients aged 19 to 95 recruited in 81 dialysis clinics between October 1995 and June 1998, and is overseen by the Johns Hopkins University School of Public Health.
The discovery of genetic associations offers the potential to direct clinical management in order to prevent ASCVD (Atherosclerotic Cardiovascular Disease) and improve survival in patients with end stage renal disease (ESRD).
Objectives:
In Collaboration with investigators of the CHOICE cohort, we propose to assess the role of variants in genes related to the inflammatory process on atherosclerotic cardiovascular disease (ASCVD) incidence.
Eligibility:
Eligibility is independent of age, race, ethnicity, and gender. However, no participants in this cohort are less than 19 years of age.
Design:
Frozen buffy coats from 871 patients will be sent to the LGD, and DNA will be extracted.
Singles nucleotide polymorphisms (SNPs) within coding regions, upstream or downstream regulatory regions or in intronic regions of candidates genes will be genotyped.
The first candidate genes under study include IL6, IL10, TGFB1, Beta Fibrinogen, LTA, and STAT3.
Blood samples and relevant clinical data will be provided by Johns Hopkins University School of Public Health, Department of Epidemiology with only numerical code which links samples and clinical data. While Johns Hopkins University will retain patient identifier information, the LGD will have no way of identifying the person from whom the blood, subsequent DNA, and clinical data are obtained.
The samples are maintained in our repository and curated through our central Laboratory database.
Destruction or loss of clinical samples or data will be recorded in our database and cannot impact the study participants in any way.
At the completion of this protocol, we will retain the samples for future use. We understand that studies subsequent to the completion of this protocol will require additional OHSR/IRB approval prior to commencement.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní místa
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21205
- Johns Hopkins University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
- INCLUSION CRITERIA:
Original eligibility criteria for enrollment in the CHOICE cohort included: 1) new onset of chronic outpatient renal replacement therapy in the last 3 months, 2) ability to give informed consent to participate in the study, 3) age 19 years or older, 4) ability to speak English or Spanish.
EXCLUSION CRITERIA:
The entire set of 871 samples available to the LGD will be analyzed. No subject will be excluded.
Studijní plán
Jak je studie koncipována?
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002 Jul;13(7):1918-27. doi: 10.1097/01.asn.0000019641.41496.1e.
- Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol. 2000 Mar;11(3):520-529. doi: 10.1681/ASN.V113520.
- Georges JL, Loukaci V, Poirier O, Evans A, Luc G, Arveiler D, Ruidavets JB, Cambien F, Tiret L. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Mol Med (Berl). 2001 Jun;79(5-6):300-5. doi: 10.1007/s001090100209.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 999905125
- 05-C-N125
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Konečné stadium onemocnění ledvin
-
National Taiwan University HospitalNeznámý
-
Hospices Civils de LyonDokončenoEnd-stage Renal Disease (ESRD)Francie
-
Ottawa Hospital Research InstituteHeart and Stroke Foundation of OntarioDokončenoEnd-stage Renal Disease (ESRD) | Nemoc ledvinKanada
-
Ionis Pharmaceuticals, Inc.BayerDokončenoEnd-stage Renal Disease (ESRD)Kanada
-
Ionis Pharmaceuticals, Inc.BayerDokončenoEnd-stage Renal Disease (ESRD)Španělsko
-
Epizon Pharma, Inc.DokončenoEnd-stage Renal Disease (ESRD)Spojené státy
-
Rockwell Medical Technologies, Inc.DokončenoEnd-stage Renal Disease (ESRD)Spojené státy, Kanada
-
University of Kansas Medical CenterDokončenoEnd-stage Renal Disease (ESRD) | Chronické onemocnění ledvin (CKD)Spojené státy
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHDokončenoEnd-stage Renal Disease (ESRD)Itálie
-
Lundquist Institute for Biomedical Innovation at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Davita...NeznámýChronické onemocnění ledvin (CKD) | End-stage Renal Disease (ESRD)Spojené státy